FDA approves enhanced software for DBS to treat Parkinson’s, essential tremor

The FDA has approved a software update for a deep brain stimulation system intended to assist clinicians in the treatment of those with Parkinson’s disease or essential tremor.

According to a release from Boston Scientific Corporation, the Vercise Neural Navigator 5 software features greater flexibility and enhanced user interface, which simplifies patient data and provides health care professionals access to advanced settings for increased therapy delivery and greater specificity to patient needs.

Developed in collaboration with Brainlab AG, the neural navigator and its partner, the Vercise Genus Deep Brain Stimulation System demonstrated a reduction in programming time by 56% and offer real-time visualization and stimulation of an individual’s unique brain anatomy, per the release.

The deep brain stimulation system (DBS) addresses Parkinson’s symptoms and essential tremor by delivering targeted electrical stimulation via surgically implanted leads in the brain connected to implantable pulse generators.

"Developing meaningful tools to help physicians provide personalized treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions,” Jim Cassidy, president, Neuromodulation, Boston Scientific, stated in the release. “Providing effective DBS therapy is complex and can be time-consuming. This software will help streamline the process and allow for more doctor-patient interaction time."